DOCSLIB.ORG

20 13 Rep Or T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
20 13 Rep Or T 2013 REPORT More Than 240 Medicines in Development for Leukemia, Lymphoma and Other Blood Cancers Every 4 minutes a person is diagnosed with leukemia, Medicines in Development lymphoma or For Leading Blood Cancers myeloma; Accounting for Application Submitted 9% of all cancers Phase III diagnosed each year Phase II Biopharmaceutical research companies • 15 each for myeloproliferative neo- Phase I are developing 241 medicines for blood plasms, such as myelofibrosis, poly- cancers—leukemia, lymphoma and cythemia vera and essential throm- 97 98 myeloma. This report lists medicines in bocythemia; and for myelodysplastic human clinical trials or under review by syndromes, which are diseases affect- the U.S. Food and Drug Administration ing the blood and bone marrow. (FDA). These medicines in development offer The medicines in development include: hope for greater survival for the thou- sands of Americans who are affected by • 98 for lymphoma, including Hodgkin these cancers of the blood. and non-Hodgkin lymphoma, which 52 affect nearly 80,000 Americans each Definitions for the cancers listed in this year. report and other terms can be found on page 27. Links to sponsor company web • 97 for leukemia, including the four sites provide more information on the major types, which affect nearly potential products. 50,000 people in the United States 24 each year. For information on the value of medi- cines, an in-depth look at current in- • 52 for myeloma, a cancer of the novation and key medical breakthroughs plasma cells, which impacts more benefiting blood cancer patients, please than 22,000 people each year in the see Medicines in Development for Leu- United States. kemia and Lymphoma 2013—Overview. emia • 24 medicines are targeting hema- tological malignancies, which affect Leuk ymphoma Myeloma L bone marrow, blood and lymph Malignancies Hematological nodes. Medicines in Development for Leukemia & Lymphoma Hematological Malignancies Product Name Sponsor Indication Development Phase* Adcetris® Millennium Pharmaceuticals treatment of CD30-positive Phase II brentuximab vedotin Cambridge, MA hematological malignancies millennium.com (Orphan Drug) Seattle Genetics (see also lymphoma) seattlegenetics.com Bothell, WA AMG 319 Amgen hematological malignancies Phase I (PI3K-delta inhibitor) Thousand Oaks, CA amgen.com anti-CD22 antibody-drug Genentech hematological malignancies Phase II conjugate South San Francisco, CA (see also lymphoma) gene.com (DCDT 2980S) anti-CD79b antibody-drug Genentech hematological malignancies Phase II conjugate South San Francisco, CA (see also lymphoma) gene.com (DCDS 4501A) AR-42 Arno Therapeutics hematological malignancies Phase I/II (pan-DAC inhibitor) Flemington, NJ arnothera.com AZD1208 AstraZeneca hematological malignancies Phase I (PIM kinase inhibitor) Wilmington, DE astrazeneca.com AZD9150 AstraZeneca hematological malignancies Phase I (STAT3 inhibitor) Wilmington, DE astrazeneca.com belinostat Spectrum Pharmaceuticals hematological malignancies Phase I (HDAC inhibitor) Henderson, NV (see also lymphoma) sppirx.com CB3304 Cougar Biotechnology hematological malignancies Phase I (noscapine) Raritan, NJ cougarbiotechnology.com darinaparsin ZIOPHARM Oncology hematological malignancies Phase II (ZIO-101) New York, NY (see also lymphoma, myeloma) ziopharm.com fostamatinib AstraZeneca hematological malignancies Phase II (Syk inhibitor) Wilmington, DE astrazeneca.com Rigel Pharmaceuticals rigel.com South San Francisco, CA GS-9973 Gilead Sciences B-cell hematological malignancies Phase I (Syk inhibitor) Foster City, CA gilead.com *For more information about a specific medicine or company in the report, please click on the provided link. 2 Medicines in Development Leukemia & Lymphoma 2013 Medicines in Development for Leukemia & Lymphoma Hematological Malignancies Product Name Sponsor Indication Development Phase Jakafi® Incyte hematological malignancies Phase II ruxolitinib Wilmington, DE incyte.com Kyprolis® Onyx Pharmaceuticals hematological malignancies Phase I carfilzomib South San Francisco, CA (see also myeloma) onyx.com MEDI-551 AstraZeneca hematological malignancies Phase II (anti-CD19 mAb) Wilmington, DE astrazeneca.com MedImmune medimmune.com Gaithersburg, MD MLN4924 Millennium Pharmaceuticals hematological malignancies Phase I (pevonedistat) Cambridge, MA millennium.com MLN8237 Millennium Pharmaceuticals hematological malignancies Phase II (alisertib) Cambridge, MA (see also lymphoma) millennium.com MLN9708 Millennium Pharmaceuticals hematological malignancies Phase I (ixazomib) Cambridge, MA (see also myeloma) millennium.com (second-generation proteasome inhibitor) moxetumomab pasudotox AstraZeneca hematological malignancies Phase I (anti-CD22 recombinant Wilmington, De astrazeneca.com immunotoxin) MedImmune medimmune.com Gaithersburg, MD nivolumab Bristol-Myers Squibb hematological malignancies Phase I (anti-PD-1) Princeton, NJ bms.com RG7112 Roche hematological malignancies Phase I (MDM2 antagonist) Nutley, NJ roche.com RG7388 Roche hematological malignancies Phase I (proto oncogene protein-c mdm2 Nutley, NJ roche.com inhibitor) SAR405838 Ascenta Therapeutics hematological malignancies Phase I (HDM2/p53 antagonist) Malvern, PA ascenta.com Sanofi US sanofi.com Bridgewater, NJ SAR650984 ImmunoGen hematological malignancies Phase I (anti-CD38 naked mAb) Waltham, MA immunogen.com Sanofi US sanofi.com Bridgewater, NJ Medicines in Development Leukemia & Lymphoma 2013 3 Medicines in Development for Leukemia & Lymphoma Leukemia Product Name Sponsor Indication Development Phase ABT-199/GDC-0199/RG7601 AbbVie relapsed/refractory chronic Phase I (Bcl-2 inhibitor) North Chicago, IL lymphocytic leukemia (CLL) abbvie.com Genentech (see also lymphoma, myeloma) gene.com South San Francisco, CA roche.com Roche Nutley, NJ Actimab-A™ Actinium Pharmaceuticals acute myeloid leukemia (AML) Phase I/II lintuzumab Ac-225 New York, NY actiniumpharmaceuticals.com aminopterin Syntrix Biosystems pediatric acute lymphoblastic Phase II Auburn, WA leukemia (ALL) syntrixbio.com Arzerra® GlaxoSmithKline first-line CLL, relapsed CLL Phase III ofatumumab Rsch. Triangle Park, NC (see also lymphoma) gsk.com (Orphan Drug) AT-101 Ascenta Therapeutics CLL Phase II completed (pan Bcl-2 inhibitor) Malvern, PA (see also lymphoma) ascenta.com AT-406 Ascenta Therapeutics acute myeloid leukemia (AML) Phase I (multi-IAP inhibitor) Malvern, PA ascenta.com Debiopharm debiopharm.com Lausanne, Switzerland bafetinib CytRx CLL Phase II completed Los Angeles, CA cytrx.com BI-811283 Boehringer Ingelheim Pharmaceuticals AML Phase I/II (aurora B kinase inhibitor) Ridgefield, CT boehringer-ingelheim.com BI-836826 Boehringer Ingelheim Pharmaceuticals CLL Phase I Ridgefield, CT boehringer-ingelheim.com BI-836858 Boehringer Ingelheim Pharmaceuticals AML Phase I Ridgefield, CT boehringer-ingelheim.com birinapant TetraLogic Pharmaceuticals AML Phase I/II Malvern, PA (see also lymphoma) tetralogicpharma.com Bismab-A™ Actinium Pharmaceuticals AML Phase I/II lintuzumab Bi-213 New York, NY actiniumpharmaceuticals.com 4 Medicines in Development Leukemia & Lymphoma 2013 Medicines in Development for Leukemia & Lymphoma Leukemia Product Name Sponsor Indication Development Phase blinatumomab Amgen ALL Phase II (AMG 103) Thousand Oaks, CA (see also lymphoma) amgen.com BMS-906024 Bristol-Myers Squibb T-cell ALL Phase I (notch inhibitor) Princeton, NJ (see also lymphoma) bms.com BMS-936564 Bristol-Myers Squibb AML, CLL, diffuse large Phase I (anti-CXCR4) Princeton, NJ B-cell leukemia bms.com (see also lymphoma, myeloma) Bosulif® Pfizer first-line Ph+ CML Phase III bosutinib New York, NY pfizer.com BP-100-1.01 Bio-Path Holdings ALL, AML, CML Phase I (liposomal Grb-2) Houston, TX (see also myelodysplastic) biopathholdings.com (Orphan Drug) calaspargase pegol Sigma-Tau Pharmaceuticals ALL in adolescents and children Phase III (Orphan Drug) Gaithersburg, MD sigmatau.com CC-292 Celgene CLL Phase I (Btk inhiitor) Summit, NJ (see also lymphoma) celgene.com CC-486 Celgene post-induction AML maintenance Phase II (nucleoside analogue) Summit, NJ (see also myelodysplastic) celgene.com Ceplene® EpiCept AML Phase III histamine Tarrytown, NY epicept.com CNDO-109 Coronado Biosciences AML Phase II (tumor-activated natural Burlington, MA coronadobiosciences.com killer cells) (Orphan Drug) CPX-351 Celator Pharmaceuticals AML Phase III (cytarabine/daunorubicin) Princeton, NJ celatorpharma.com (Orphan Drug) crenolanib AROG Pharmaceuticals AML Phase II (CP-868-596) Dallas, TX arogpharma.com CTL019 Novartis Pharmaceuticals CLL Phase II (CAR T-cell therapy) East Hanover, NJ novartis.com University of Pennsylvania Philadelphia, PA CWP232291 JW Pharmaceutical AML Phase I Seoul, South Korea Medicines in Development Leukemia & Lymphoma 2013 5 Medicines in Development for Leukemia & Lymphoma Leukemia Product Name Sponsor Indication Development Phase Dacogen® Eisai AML application submitted decitabine Woodcliff Lake, NJ eisai.com (Orphan Drug) -------------------------------------- ----------------------------------------- pediatric AML Phase II eisai.com DFP-10917 Delta-Fly Pharma ALL, AML Phase I/II (cell cycle inhibitor) Tokushima, Japan dinaciclib Merck CLL Phase III (SOK inhibitor) Whitehouse Station, NJ merck.com (Orphan Drug) elesclomol Synta Pharmaceuticals AML Phase I Lexington, MA syntapharma.com ENMD-2076 EntreMed AML Phase I completed (Orphan Drug) Rockville, MD (see also myeloma) entremed.com entinostat Syndax Pharmaceuticals leukemia Phase II Waltham, MA (see also lymphoma) syndax.com
Load more

Recommended publications
  • Comment Letter
    July 23, 2008 Subject: Follow-up on July 22 Meeting Dr. Sirri et al.: I thank you for meeting with Ken Salomon, John Welborn and me yesterday afternoon to discuss Reg SHO, naked short selling and the SEC's recent emergency order. As a follow-up, I want to emphasize the following points: 1. OSTK continues to believe that it is critical that the SEC extend the pre-borrow requirement of the emergency order to the entire market, not just the 19 select companies. OSTK requests that the SEC promptly undertake swift rulemaking so that this protection applies fairly across the market. 2. OSTK continues to support the prompt and full elimination of the option market maker exception, an exception that swallows up the good intentions of Reg SHO. During yesterday's meeting, we discussed the relationship between the markets for equities and their corresponding derivatives (including listed options). You stated that options market makers enjoy an exception from the Reg SHO requirement that they locate and/or deliver shares when hedging against options positions. I am not sure that I would read Reg SHO to say that. However, under your theory, if an options market maker sells a put with a 6- month expiration, then that same market maker has the legal right to naked short and fail to deliver an equivalent amount of the underlying equity (leaving the option market maker "delta neutral”) for six months. This exception is unnecessary and open to abuse/manipulation, particularly with the married puts that often occur in Reg SHO threshold securities.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Highlights from the Pan Pacific Lymphoma Conference
    October 2011 A SPECIAL MEETING REVIEW EDITION Volume 9, Issue 10, Supplement 24 Highlights From the Pan Pacific Lymphoma Conference August 15–19, 2011 Kauai, Hawaii Special Reporting on: • Aggressive T-Cell Lymphomas • Novel Agents With Activity in CLL/SLL • PTCL—Update on Novel Therapies • Agents Targeting the Stromal Elements of the Lymph Node • Inducing Apoptosis in Lymphoma Cells Through Novel Agents With Expert Commentary by: Bruce D. Cheson, MD Deputy Chief Division of Hematology-Oncology Head of Hematology Lombardi Comprehensive Cancer Center Georgetown University Hospital Washington, DC Eb: E W Th O N www.clinicaladvances.com ENGINEERING T H E N E X T GENERATION OF ANTIBODY-DRUG CONJUGATES 003203_sgncor_adcadvcaho_fa4.indd 2 8/25/11 11:13 AM An innovative approach to improving outcomes in patients with cancer Antibody-drug conjugates (ADCs) use a conditionally stable linker to combine the targeting specificity of monoclonal antibodies with the tumor-killing power of potent cytotoxic agents.1,2 This could allow potent drugs to be delivered directly to tumor cells with minimal systemic toxicity. Optimizing the parameters for clinical success Scientists at Seattle Genetics are focused on parameters critical to the effective performance of ADCs, including target antigen selection,3,4 linker stability5-7 and potent cytotoxic agents.4,7,8 Elements of an antibody-drug conjugate Linker ADCs link precision and Antibody attaches the cytotoxic agent to specific for a tumor-associated the antibody. Newer linker potency for greater activity
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Monoclonal Antibody-Based Therapy As a New Treatment Strategy in Multiple Myeloma
    Leukemia (2012) 26, 199–213 & 2012 Macmillan Publishers Limited All rights reserved 0887-6924/12 www.nature.com/leu REVIEW Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma NWCJ van de Donk1, S Kamps1, T Mutis2 and HM Lokhorst1 1Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands and 2Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands The introduction of autologous stem cell transplantation the myeloma patients achieved a partial response (PR) or stable combined with the introduction of immunomodulatory drugs disease following rituximab therapy. All these patients expressed (IMiDs) and proteasome inhibitors has significantly improved CD20 on their myeloma cells.2 However, as only B15–20% of survival of multiple myeloma patients. However, ultimately the majority of patients will develop refractory disease, indicating all myeloma patients express CD20 on their bone marrow the need for new treatment modalities. In preclinical and clinical plasma cells, new targets for immunotherapy need to be studies, promising results have been obtained with several identified. The search for other targets has led to the develop- monoclonal antibodies (mAbs) targeting the myeloma tumor ment of mAbs targeting growth factor receptors or adhesion cell or the bone marrow microenvironment. The mechanisms molecules on myeloma cells. Other newly developed mAbs underlying the therapeutic efficacy of these mAbs include are directed against cellular or non-cellular components of the direct induction of tumor cell apoptosis via inhibition or activation of target molecules, complement-dependent cyto- bone marrow microenvironment, resulting in the neutraliza- toxicity and antibody-dependent cell-mediated cytotoxicity tion of growth factors, inhibition of angiogenesis, modulation (ADCC).
    [Show full text]
  • European Biotechnology | Summer Edition | Vol
    I S S N 2 3 6 4 - 2 351 | A 6 0 711 | Interview Hospira’s Paul Greenland talks European about the launch Life Sciences and of the first mAb Industry Magazine biosimilar and the new challenges in Biotechnology Summer Edition 2015 | Volume 14 | 20 € development. Financing European biotech companies have added crowdinvesting to the fi nancing toolbox Nagoya Protocol Poor implementation of benefi t sharing could block Tracking biotech innovation in Europe Antibiotics New EU fi nancing instrument to close funding gap in high- stealthy risk antibiotic development EuroBioFairsCompass The unique guide to the top life killers sciences events in the second half of 2015 FREE EXCERPT Liquid Biopsy 4 CONTENTS European Biotechnology | Summer Edition | Vol. 14 | 2015 FREE EXCERPT COVER STORY INSIGHT EUROPE REGIONAL NEWS 6 European Commission opens 42 Northern Europe: fl oodgates for GM imports Sweden, Denmark, Finland, and Norway 10 First genome-edited crops to be stamped non-GMO by Member 44 Western Europe: States; Heard in Brussels France, Belgium, The Netherlands and the UK 12 European Commission and Euro- pean Investment Bank set to 46 Central Europe: launch new fi nancing instrument Austria, Germany and Switzerland for high-risk antibiotics develop- ment; Horizon2020 call focuses 48 Southern Europe: on personalised medicine; UK lags Italy, Spain, Portugal, Cyprus & Malta behind EU in fi ght against cancer; MEPs demand no dilution of EU life 50 Eastern Europe: sciences rules through TTIP Poland and the Czech Republic ECONOMY PICK & MIX 22 Interview: Paul
    [Show full text]
  • Como Prometió Fidel, En Junio Del 2001, Cuando Dijo: ¡Volverán!, Arribaron Hoy a Nuestra Patria, Gerardo, Ramón Y Antonio.” Raúl
    EDITOR: NOEL GONZÁLEZ GOTERA Nueva Serie. Número 166 Diseño: Lic. Roberto Chávez y Liuder Machado. Semana 131214 - 191214 Foto: Lic. Belkis Romeu e Instituto Finlay La Habana, Cuba. “Como prometió Fidel, en junio del 2001, cuando dijo: ¡Volverán!, arribaron hoy a nuestra Patria, Gerardo, Ramón y Antonio.” Raúl “Desde mi elección como Presidente de los Consejos de Estado y de Ministros, he reiterado en múltiples ocasiones, nuestra disposición a sostener con el gobierno de los Estados Unidos un diálogo respetuoso, basado en la igualdad soberana, para tratar los más diversos temas de forma recíproca, sin menoscabo a la independencia nacional y la autodeterminación de nuestro pueblo… Resultado de un diálogo al más alto nivel, que incluyó una conversación telefónica que sostuve ayer con el Presidente Barack Obama, se ha podido avanzar en la solución de algunos temas de interés para ambas naciones... Esta decisión del Presidente Obama, merece el respeto y reconocimiento de nuestro pueblo. … Proponemos al Gobierno de los Estados Unidos adoptar medidas mutuas para mejorar el clima bilateral y avanzar hacia la normalización de los vínculos entre nuestros países, basados en los principios del Derecho Internacional y la Carta de las Naciones Unidas… Cuba reitera su disposición a sostener cooperación en los organismos multilaterales, como la Organización de Naciones Unidas… Los progresos alcanzados en los intercambios sostenidos demuestran que es posible encontrar solución a muchos problemas… Como hemos repetido, debemos aprender el arte de convivir, de forma civilizada, con nuestras diferencias…“ Raúl Castro Ruz, La Habana, 17 de diciembre de 2014. Fragmentos de su alocución. 1 "Indeed, we've seen the benefits of cooperation between our countries before.
    [Show full text]
  • Molecular Targeted Therapies for Indolent Lymphomas: Where Are
    Hematology Meeting Reports 2009;3(3):4–9 SESSION I G. Saglio Molecular targeted therapies for indolent G. Parvis M. Bosa lymphomas: where are we? Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole, Orbassano, TO, Italy During the last decade the analysis11 suggested that mainte- development of new drugs for the nance therapy with rituximab, treatment of hematologic malig- either as four weekly infusions nancies has become really prom- every 6 months or as a single infu- ising. This innovative drug devel- sion every 2-3 months, should be opment is based on the translation added to standard therapy for into biochemical pharmacology patients with relapsed or refracto- of specific alterations of biologi- ry follicular lymphoma after suc- cal functions affecting tumour cessful induction therapy, to cells1. One of the most important improve progression-free and examples is imatinib: it showed overall survival. In contrast, pre- that it was possible to nullify the viously untreated patients seem pathognomic genetic lesion of not to acquire the same benefit chronic myelogenous leukemia from the maintenance treatment (CML). Drugs targeting unique (i.e. it prolongs the time to pro- disease-specific pathways have gression but does not prolong sur- also found potential applicability vival).12-13 in treating malignancies such as The data recently showed at CD20-positive non-Hodgkin’s 2008 ASH Meeting, coming from lymphoma (rituximab), follicular the clinical phase III studies lymphoma (Bcl-2-targeted named CLL8 and REACH, defi- agents2-6) and other B-cell neo- nitely support the employment of plasms (splenic tyrosine kinase rituximab in addition to chemo- [Syk] inhibitors;7-9 IkB kinase therapy (the standard regimen inhibitors10).
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Cancer Vaccine Therapies: Failures and Future Opportunities Michael D
    Cancer Vaccine Therapies: Failures and Future Opportunities Michael D. Becker, Janet Dally, and Jeffrey Martini, Ph.D. Michael D. Becker President & CEO [email protected] Janet Dally Senior Vice President [email protected] Jeffrey Martini, Ph.D. Vice President [email protected] MD Becker Partners LLC 12 Penns Trail, #231 Newtown, PA 18940 Main phone: 267-756-7094 Email: [email protected] Web: www.mdbpartners.com www.mdbpartners.com Copyright © 2010 MD Becker Partners LLC All rights reserved MD Becker Partners LLC [This page intentionally left blank] Cancer Vaccine Therapies: Failures and Future Opportunities Page 2 MD Becker Partners LLC MD Becker Partners’ reports are limited publications that contain valuable information provided to a select group of customers. Our reports are for our customers’ internal use and not for general publication or disclosure to third parties. No part of this report may be given, lent, resold, or disclosed to non-customers without written permission. Furthermore, no part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the permission of the publisher. For additional information, please refer to Appendix G: Legal Disclaimer. For information regarding permission, write: MD Becker Partners LLC 12 Penns Trail, #231 Newtown, PA 18940 Main phone: 267-756-7094 Email: [email protected] Web: www.mdbpartners.com MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry, including pharmaceuticals, biotechnology, and medical devices. We also work with venture capitalists, institutional investors, and others that provide capital to these companies.
    [Show full text]
  • Orphan Drug Dummy File
    Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in Sigma-Tau levocarnitine Carnitor 11/15/1989 valproic acid toxicity Pharmaceuticals, Inc. 2 1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving Pediatric thalidomide n/a 9/19/1988 bone marrow transplantation Pharmaceuticals, Inc. 3 A Diagnostic for the management Advanced Imaging Theranost 68 Ga RGD n/a 10/1/2014 of Moyamoya disease (MMD) Projects, LLC (AIP) 4 Cadila heat killed Mycobacterium w Pharmaceuticals immunomodulator Cadi Mw 9/3/2004 Active tuberculosis Limited, Inc. 5 Adjunct to cytokine therapy in the treatment of acute myeloid Histamine Ceplene 12/15/1999 leukemia. EpiCept Corporation 6 Adjunct to surgery in cases of rh-microplasmin, ocriplasmin Jetrea 3/16/2004 pediatric vitrectomy ThromboGenics Inc. 7 Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or Ferring Laboratories, Somatostatin Zecnil 6/20/1988 pancreas. Inc. Page 1 of 377 Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with Allos Therapeutics, efaproxiral n/a 7/28/2004 breast cancer Inc.
    [Show full text]
  • Towards Novel Paradigms for Cancer Therapy
    Oncogene (2011) 30, 1–20 & 2011 Macmillan Publishers Limited All rights reserved 0950-9232/11 www.nature.com/onc REVIEW Towards novel paradigms for cancer therapy V Pavet1, MM Portal1, JC Moulin1,2, R Herbrecht2 and H Gronemeyer1 1Department of Cancer Biology, Institut de Ge´ne´tique et de Biologie Mole´culaire et Cellulaire (IGBMC), Illkirch, Alsace, France and 2Department of Oncology and Hematology, Hoˆpitaux Universitaires de Strasbourg, Strasbourg, France Cancer is a complex progressive multistep disorder that normal cell toward a malignant derivative. This process results from the accumulation of genetic and epigenetic shapes each tumor in such a dynamic and unique way abnormalities, which lead to the transformation of normal that it is extremely difficult to determine the alterations cells into malignant derivatives. Despite enormous progress that cause, maintain and spread the disease (Greenman in the understanding of cancer biology including the et al., 2007; Wood et al., 2007). decryption of multiple regulatory networks governing cell Historically, solid tumors have been treated by growth and death, and despite the possibility of analyzing surgery for the past 4000 years (http://www.cancer.org/ (epi)genetic deregulation at the genome-wide scale, cancer- docroot/CRI/content/CRI_2_6x_the_history_of_cancer_ targeted therapy is still the exception. In fact, to date there 72.asp?sitearea ¼ ). It was only after the discovery of are still far too few examples of therapies leading to cure; X-rays at the end of the nineteenth century that treatment-derived toxicity is a major issue, and cancer radiotherapy emerged as a novel therapeutic approach. remains to be one of the largest causes of death worldwide.
    [Show full text]